HST Global, Inc. Sets New Standards in the Treatment of Stage IV Breast Cancer!
HST Global, Inc., (OTCBB: HTSC) announced today it is meeting with 72% efficacy in pre-clinical treatment of Stage IV cancer in a test of 250 patients. The highlight of the study is in stage IV breast cancer where they have met with 72% efficacy with 58 patients over 2 1/2 years with its drug candidate Salicinium.
Ronald Howell President & CEO of HST Global, Inc. stated, “We are encouraged by these results and are looking forward to subjecting the study to more rigorous tests to support eventual commercialization.”
About the Study:
HST Global, Inc., currently has the rights to a pre-clinical outcome-based study using the pre-clinical drug trade named “Salicinium”. This natural substance, which is plant-derived, is both oral and a parenteral active inhibitor of certain fermenting enzyme dynamics in the cancer cells. Clinical studies demonstrate that Salicinium alters malignant cell fermentation dynamics, blocks cell division (mitosis), and causes fermenting cancer cells to lose their ability to withstand innate immune reactions.
Given parenterally, in the form of the Forsythe Immune Therapy #2, the I.V. contains proprietary amounts of normal saline, magnesium chloride, vitamin B6, vitamin B12, B complex, folic acid, vitamin C, L-Lysine, zinc, glutathione, and the main ingredient “Salicinium”. The preparation is succussed at the time of the patient’s visit, and it is prepared in approximately a 1:70 dilution.
The purpose of the pre-clinical outcome-based study in Stage IV adult cancers is to study efficacy and safety issues. All patients coming to the clinical are given the following choices:
1. Conventional chemotherapy, either first, second or third line, as appropriate to the patient's prior history. 2. Conventional chemotherapy, either standard or low-dose fractioned, with Salicinium; 3. Conventional dose or low-dose fractioned chemotherapy with Salicinium and other complimentary products; 4. Salicinium along with other complimentary therapies; 5. Salicinium alone; 6. Insulin potentiated therapy using standard chemotherapy with Salicinium; and 7. Any of the above plus hormonal therapies.
This study was carried out from June of 2005 through March of 2008, with 250 Stage IV cancer patients under study.
The advantages of the pre-clinical study were to show efficacy and safety, and freedom from adverse toxicities and adverse side-effects. The conclusion of the study was that Salicinium is a novel, homeopathic, immune boosting therapy that when used alone in breast cancer, isolated from other cancers, showed an overall response rate of 79% at 33 months.
When Salicinium was used in combination with Poly-MVA and/or chemotherapy, the overall response rate was 75%.
These results compared favorably with conventional chemotherapy alone which, in five years in the allopathic literature from 2004, showed only a 2.1% survival rate in the United States with any form of chemotherapy alone.
It is important to note that this product is compatible with other complimentary therapies, which vector in on the metabolism of the cancer cell in a different matter.
Also of great importance is the fact that there were no significant adverse events in these 250 patients using Salicinium, even when used with low-dose fractioned chemotherapy.
The pre-clinical outcome-based study is available for review, with all the statistics outline, which demonstrates the above positive effects.
HST Global, Inc. makes no representation that the US Food and Drug Administration or any other regulatory agency will allow this Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration. Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound; referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well-controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.
About HST Global, Inc.
HST Global, Inc. is a development stage biotechnology company that acquires and develops innovative products for the treatment of cancer. We focus on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, and then developing those drug candidates for commercial use.
HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.